Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Patricio Eduardo Yanez"'
Autor:
Ricardo Bruges, Pamela Salman, Ruben Dario Kowalyszyn, M. Li, Lucjan Wyrwicz, Valerie Poulart, Michalis V. Karamouzis, Arinilda Silva Campos Bragagnoli, Roberto Pazo-Cid, Marcelo Garrido, Yelena Y. Janjigian, Tomasz Skoczylas, Lin Shen, Mustapha Tehfe, Kensei Yamaguchi, Ming Lei, Michael Schenker, Thomas Zander, H. Xiao, Erika Hitre, Kynan Feeney, Markus Moehler, Kaoru Kondo, Kohei Shitara, Patricio Eduardo Yanez, Tianshu Liu, Dana Cullen, James M. Cleary, Jaffer A. Ajani
Publikováno v:
The Lancet. 398:27-40
First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line
Autor:
Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Raymond S. McDermott, Nuria Sala González, Peter C.C. Fong, Richard Greil, Maria De Santis, Patricio Eduardo Yanez, Yi-Hsiu Huang, Stephen Begbie, Felipe Rey, Gero Kramer, Hiroyoshi Suzuki, Todd L. Saretsky, Sameer R. Ghate, Yi Cui, Jeri Kim, Evan Y. Yu
Publikováno v:
Journal of Clinical Oncology. 41:131-131
131 Background: The phase 3, randomized KEYLYNK-010 trial (NCT03834519) of pembro + ola vs next-generation hormonal agent (NHA) abi or enza did not significantly improve rPFS or OS in molecularly unselected pts with mCRPC treated with prior NHA and d
Autor:
Patricio Eduardo Yanez, Irit Ben-Aharon, Carlos Rojas, Daniel Acosta Eyzaguirre, Ayala Hubert, Hernan Araya, Deirdre Jill Cohen, Li-Yuan Bai, François Ghiringhelli, Lucjan Wyrwicz, Yelena Y. Janjigian, Josep Tabernero, Eric Van Cutsem, Shukui Qin, Jianming Xu, Anran Wang, Mary Gwen Miller, Chie-Schin Shih, Pooja Bhagia, Kohei Shitara
Publikováno v:
Journal of Clinical Oncology. 41:411-411
411 Background: LEAP-015 (NCT04662710) is a randomized, open-label, 2-part, phase 3 study of the safety and efficacy of lenvatinib + pembrolizumab + chemotherapy as a first-line treatment for advanced/metastatic gastroesophageal adenocarcinoma. We re
Autor:
Lie Li, Lucjan Wyrwicz, Yelena Y. Janjigian, Patricio Eduardo Yanez, Pooja Bhagia, Lin Shen, Suxia Luo, Kohei Shitara, Oleksii Kolesnik, Eric Van Cutsem, Yong Tang, Olga Barajas, Yuxian Bai, Akihito Kawazoe, Chie-Schin Shih, Hyun Cheol Chung, Josep Tabernero, Shukui Qin, Sara Lonardi
Publikováno v:
Journal of Clinical Oncology. 39:4013-4013
4013 Background: Trastuzumab (tras) plus chemotherapy (chemo) is standard-of-care (SOC) 1L therapy for HER2+ metastatic G/GEJ cancer. In two phase 2 studies, tras, chemo, and pembrolizumab (pembro) in combination showed promising efficacy and managea
Autor:
Lucjan Wyrwicz, Patricio Eduardo Yanez, Kohei Shitara, Mustapha Tehfe, Arteid Memaj, Marcelo Garrido, Pamela Salman, Tomasz Skoczylas, Ming Lei, Arinilda Campos Bragagnoli, Tianshu Liu, Markus Moehler, Michael Schenker, Lin Shen, Dana Cullen, Kensei Yamaguchi, Mingshun Li, H. Xiao, Jaffer A. Ajani, Yelena Y. Janjigian
Publikováno v:
Journal of Clinical Oncology. 39:4002-4002
4002 Background: CheckMate 649 is the largest randomized, global phase 3 study of 1L programmed death (PD)-1 inhibitor–based therapy in GC/GEJC/EAC. 1L NIVO + chemo demonstrated superior overall survival (OS) vs chemo, with progression-free surviva
Autor:
M. Li, Kaoru Kondo, Ming Lei, T. Liu, Lucjan Wyrwicz, Michael Schenker, Marcelo Garrido, Tomasz Skoczylas, L. Shen, Jaffer A. Ajani, Yelena Y. Janjigian, Valerie Poulart, A. Campos Bragagnoli, Markus Moehler, Dana Cullen, K. Shitara, Kensei Yamaguchi, Mustapha Tehfe, Pamela Salman, Patricio Eduardo Yanez
Publikováno v:
Annals of Oncology. 31:S1191
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.